Summit Therapeutics SMMT After tax total accumulated other comprehensive income (loss), Net impairment losses recognized in earnings
Discontinued — last reported Q4 '25
After tax total accumulated other comprehensive income (loss), Net impairment losses recognized in earnings at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax.
The official record: Summit Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's after tax total accumulated other comprehensive income (loss), net impairment losses recognized in earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's after tax total accumulated other comprehensive income (loss), net impairment losses recognized in earnings?
- Summit Therapeutics (SMMT) reported after tax total accumulated other comprehensive income (loss), net impairment losses recognized in earnings of $0 in Q4 2025.
- What does after tax total accumulated other comprehensive income (loss), net impairment losses recognized in earnings mean?
- The amount of previously unrealized investment losses that have now been recognized as a formal loss in the income statement.
- How do you interpret after tax total accumulated other comprehensive income (loss), net impairment losses recognized in earnings?
- An increase indicates that the company is recognizing losses on its investment portfolio, which may signal deteriorating asset quality.
- How does after tax total accumulated other comprehensive income (loss), net impairment losses recognized in earnings compare across companies?
- Standard for companies with significant investment portfolios; peers in the financial or biotech sector may report this periodically.